Gene therapy: A primer for neurosurgeons

被引:13
作者
Chiocca, EA [1 ]
机构
[1] Massachusetts Gen Hosp, Mol Neurooncol Lab, Neurosurg Serv, Brain Tumor Serv, Boston, MA 02114 USA
关键词
cerebral ischemia; gene therapy; gliomas; Parkinson's disease; spinal fusion;
D O I
10.1227/01.NEU.0000073532.05714.2B
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
GENE THERAPY INVOLVES the transfer of genes into cells with therapeutic intent. Although several methods can accomplish this, vectors based on viruses still provide the most efficient approach. For neurosurgical purposes, preclinical and clinical applications in the areas of glioma therapy, spinal neurosurgery, and neuroprotection for treatment of Parkinson's disease and cerebral ischemia are reviewed. In general, therapies applied in the neurosurgical realm have proven relatively safe, despite occasional, well-publicized cases of morbidity and death in non-neurosurgical trials. However, continued clinical and preclinical research in this area is critical, to fully elucidate potential toxicities and to generate truly effective treatments that can be applied in neurological diseases.
引用
收藏
页码:364 / 373
页数:10
相关论文
共 94 条
[1]   In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector [J].
Alden, TD ;
Pittman, DD ;
Hankins, GR ;
Beres, EJ ;
Engh, JA ;
Das, S ;
Hudson, SB ;
Kerns, KM ;
Kallmes, DF ;
Helm, GA .
HUMAN GENE THERAPY, 1999, 10 (13) :2245-2253
[2]   Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice [J].
Amin-Hanjani, S ;
Stagliano, NE ;
Yamada, M ;
Huang, PL ;
Liao, JK ;
Moskowitz, MA .
STROKE, 2001, 32 (04) :980-985
[3]   NEURAL-TARGETED GENE-THERAPY FOR RODENT AND PRIMATE HEMIPARKINSONISM [J].
ANTON, R ;
KORDOWER, JH ;
MAIDMENT, NT ;
MANASTER, JS ;
KANE, DJ ;
RABIZADEH, S ;
SCHUELLER, SB ;
YANG, J ;
RABIZADEH, S ;
EDWARDS, RH ;
MARKHAM, CH ;
BREDESEN, DE .
EXPERIMENTAL NEUROLOGY, 1994, 127 (02) :207-218
[4]   Convection-enhanced delivery of AAV vector in parkinsonian monkeys;: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach [J].
Bankiewicz, KS ;
Eberling, JL ;
Kohutnicka, M ;
Jagust, W ;
Pivirotto, P ;
Bringas, J ;
Cunningham, J ;
Budinger, TF ;
Harvey-White, J .
EXPERIMENTAL NEUROLOGY, 2000, 164 (01) :2-14
[5]   ATTENUATION OF STROKE SIZE IN RATS USING AN ADENOVIRAL VECTOR TO INDUCE OVEREXPRESSION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN BRAIN [J].
BETZ, AL ;
YANG, GY ;
DAVIDSON, BL .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1995, 15 (04) :547-551
[6]  
Björklund A, 1999, J GENE MED, V1, P223
[7]   Towards a neuroprotective gene therapy for Parkinson's disease:: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model [J].
Björklund, A ;
Kirik, D ;
Rosenblad, C ;
Georgievska, B ;
Lundberg, C ;
Mandel, RJ .
BRAIN RESEARCH, 2000, 886 (1-2) :82-98
[8]   Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans - A prospective, randomized clinical pilot trial - 2002 Volvo Award in clinical studies [J].
Boden, SD ;
Kang, J ;
Sandhu, H ;
Heller, JG .
SPINE, 2002, 27 (23) :2662-2673
[9]   GENE-THERAPY OF PARKINSON DISEASE-MODEL RAT BY DIRECT-INJECTION OF PLASMID DNA-LIPOFECTIN COMPLEX [J].
CAO, L ;
ZHENG, ZC ;
ZHAO, YC ;
JIANG, ZH ;
LIU, ZG ;
CHEN, SD ;
ZHOU, CF ;
LIU, XY .
HUMAN GENE THERAPY, 1995, 6 (11) :1497-1501
[10]   Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [J].
Cavazzana-Calvo, M ;
Hacein-Bey, S ;
Basile, CD ;
Gross, F ;
Yvon, E ;
Nusbaum, P ;
Selz, F ;
Hue, C ;
Certain, S ;
Casanova, JL ;
Bousso, P ;
Le Deist, F ;
Fischer, A .
SCIENCE, 2000, 288 (5466) :669-672